UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial

Journal of cystic fibrosis, 2015-03, Vol.14 (2), p.219-227

2015

Link zum Volltext

Verfügbarkeit prüfen

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis

Journal of cystic fibrosis, 2017-09, Vol.16 (5), p.607-615

2017

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported respiratory symptoms in cystic fibrosis

Journal of cystic fibrosis, 2009-07, Vol.8 (4), p.245-252

2009

Link zum Volltext

Verfügbarkeit prüfen

65 Physician assessment of blinded adverse events in RCTs in cystic fibrosis

Journal of cystic fibrosis, 2017-06, Vol.16, p.S81-S81

2017

Link zum Volltext

Verfügbarkeit prüfen

Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: The early intervention in cystic fibrosis exacerbation (eICE) trial

Contemporary clinical trials, 2013-11, Vol.36 (2), p.460-469

2013

Link zum Volltext

Verfügbarkeit prüfen

188 Standardized treatment of pulmonary exacerbations (STOP) study: Clinical presentations of pulmonary exacerbations

Journal of cystic fibrosis, 2015-06, Vol.14, p.S106-S106

2015

Link zum Volltext

Verfügbarkeit prüfen

189 Standardized treatment of pulmonary exacerbation (STOP) study: Symptomatic treatment response

Journal of cystic fibrosis, 2015-06, Vol.14, p.S106-S106

2015

Link zum Volltext

Verfügbarkeit prüfen

WS07.1 Standardized treatment of pulmonary exacerbations (STOP) study: Treatment goals for pulmonary exacerbations

Journal of cystic fibrosis, 2015-06, Vol.14, p.S13-S13

2015

Link zum Volltext

Verfügbarkeit prüfen

54 Relationship between rate of percent predicted FEV1 (ppFEV1 ) decline and baseline and acute change in ppFEV1 in patients (pts) with cystic fibrosis (CF) treated with lumacaftor/ivacaftor (LUM/IVA)

Journal of cystic fibrosis, 2017-06, Vol.16, p.S78-S78

2017

Link zum Volltext

Verfügbarkeit prüfen

WS02.1 Efficacy of a protocol for eradication of newly acquired MRSA: Results of the STAR-too trial

Journal of cystic fibrosis, 2015-06, Vol.14, p.S3-S3

2015

Link zum Volltext

Verfügbarkeit prüfen

The association of month of birth with atopy in adult patients with asthma and rhinitis in Anatolia, Turkey

Allergologia et immunopathologia, 2012-11, Vol.40 (6), p.346-351

2012

Link zum Volltext

Verfügbarkeit prüfen

336: Pre-Obese and Obese Patients with Idiopathic Pulmonary Fibrosis Are at High Risk for Early Mortality after Double Transplantation

The Journal of heart and lung transplantation, 2010-02, Vol.29 (2), p.S113-S113

2010

Link zum Volltext

Verfügbarkeit prüfen

WS7.3 Once-daily liposomal amikacin for inhalation is noninferior to twice-daily tobramycin inhalation solution in improving pulmonary function in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa

Journal of cystic fibrosis, 2014-06, Vol.13, p.S15-S15

2014

Link zum Volltext

Verfügbarkeit prüfen

AI1 A MACHINE LEARNING APPROACH TO PREDICTING MORTALITY IN CYSTIC FIBROSIS

Value in health, 2020-05, Vol.23, p.S1-S1

2020

Link zum Volltext

Verfügbarkeit prüfen

EPS7.01 A survey of United States cystic fibrosis physicians’ perspectives on lung transplant referral in the era of highly effective modulator therapy

Journal of cystic fibrosis, 2024-06, Vol.23, p.S53-S53

2024

Link zum Volltext

Verfügbarkeit prüfen

1: Focusing on the Future: Development of a Predictive Model for Long-Term Survival

The Journal of heart and lung transplantation, 2009-02, Vol.28 (2), p.S65-S65

2009

Link zum Volltext

Verfügbarkeit prüfen

WS01.01 Antipseudomonal treatment decisions during cystic fibrosis exacerbation management

Journal of cystic fibrosis, 2022-06, Vol.21, p.S1

2022

Link zum Volltext

Verfügbarkeit prüfen

P096 Effect of acute systemic corticosteroids on clinical outcomes in cystic fibrosis pulmonary exacerbations

Journal of cystic fibrosis, 2023-06, Vol.22, p.S93-S93

2023

Link zum Volltext

Verfügbarkeit prüfen

Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation

Journal of cystic fibrosis, 2022-07, Vol.21 (4), p.574-580

2022

Link zum Volltext

Verfügbarkeit prüfen

217: Caregivers of Lung Transplant Recipients Exhibit High Risk for Psychological Symptoms

The Journal of heart and lung transplantation, 2008, Vol.27 (2), p.S139-S139

2008

Link zum Volltext

Verfügbarkeit prüfen

Antipseudomonal treatment decisions during CF exacerbation management

Journal of cystic fibrosis, 2022-09, Vol.21 (5), p.753-758

2022

Link zum Volltext

Verfügbarkeit prüfen

WS08.02 Contemporary incidence of cystic fibrosis in Canada and the United States

Journal of cystic fibrosis, 2022-06, Vol.21, p.S15-S16

2022

Link zum Volltext

Verfügbarkeit prüfen

Building global development strategies for cf therapeutics during a transitional cftr modulator era

Journal of cystic fibrosis, 2020-09, Vol.19 (5), p.677-687

2020

Link zum Volltext

Verfügbarkeit prüfen

310: Impact of the lung allocation score on disease transplanted and post-transplant survival

The Journal of heart and lung transplantation, 2007, Vol.26 (2), p.S171-S171

2007

Link zum Volltext

Verfügbarkeit prüfen

Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis

Journal of cystic fibrosis, 2008-03, Vol.7 (2), p.147-153

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis

Patient-reported respiratory symptoms in cystic fibrosis

65 Physician assessment of blinded adverse events in RCTs in cystic fibrosis

Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: The early intervention in cystic fibrosis exacerbation (eICE) trial

188 Standardized treatment of pulmonary exacerbations (STOP) study: Clinical presentations of pulmonary exacerbations

189 Standardized treatment of pulmonary exacerbation (STOP) study: Symptomatic treatment response

WS07.1 Standardized treatment of pulmonary exacerbations (STOP) study: Treatment goals for pulmonary exacerbations

54 Relationship between rate of percent predicted FEV1 (ppFEV1 ) decline and baseline and acute change in ppFEV1 in patients (pts) with cystic fibrosis (CF) treated with lumacaftor/ivacaftor (LUM/IVA)

WS02.1 Efficacy of a protocol for eradication of newly acquired MRSA: Results of the STAR-too trial

The association of month of birth with atopy in adult patients with asthma and rhinitis in Anatolia, Turkey

336: Pre-Obese and Obese Patients with Idiopathic Pulmonary Fibrosis Are at High Risk for Early Mortality after Double Transplantation

WS7.3 Once-daily liposomal amikacin for inhalation is noninferior to twice-daily tobramycin inhalation solution in improving pulmonary function in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa

AI1 A MACHINE LEARNING APPROACH TO PREDICTING MORTALITY IN CYSTIC FIBROSIS

EPS7.01 A survey of United States cystic fibrosis physicians’ perspectives on lung transplant referral in the era of highly effective modulator therapy

1: Focusing on the Future: Development of a Predictive Model for Long-Term Survival

WS01.01 Antipseudomonal treatment decisions during cystic fibrosis exacerbation management

P096 Effect of acute systemic corticosteroids on clinical outcomes in cystic fibrosis pulmonary exacerbations

Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation

217: Caregivers of Lung Transplant Recipients Exhibit High Risk for Psychological Symptoms

Antipseudomonal treatment decisions during CF exacerbation management

WS08.02 Contemporary incidence of cystic fibrosis in Canada and the United States

Building global development strategies for cf therapeutics during a transitional cftr modulator era

310: Impact of the lung allocation score on disease transplanted and post-transplant survival

Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis

Suchergebnisse filtern